Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lennox-Gastaut syndrome

- PMLiVE

Novavax’s COVID-19 vaccine candidate receives EC approval for use as a booster

Nuvaxovid induced a ‘robust antibody response’ when used as a heterologous third booster dose

- PMLiVE

Novartis’ Scemblix receives EC approval for chronic myeloid leukaemia

It is estimated that more than 6,300 people will be diagnosed with CML in Europe every year

- PMLiVE

Janssen’s teclistamab granted conditional marketing authorisation by EC

The decision makes teclistamab the first bispecific antibody worldwide to be approved for patients with relapsed and refractory multiple myeloma

- PMLiVE

EC approves Celltrion Healthcare’s Vegzelma for multiple cancer types

The biosimilar to Genentech's Avastin was found to be highly similar to the reference product

- PMLiVE

AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval

Breast cancer is the most diagnosed type of cancer worldwide, with an estimated 2.3 million patients diagnosed in 2020

- PMLiVE

GSK to supply 85 million doses of pandemic influenza vaccine to EU

The company has signed a contract for the reservation of future production and supply of its pandemic influenza vaccine, Adjupanrix, to support pandemic preparedness in Europe

- PMLiVE

European Commission approves potential new treatment for Pompe disease

Nexviadyme is the first and only newly approved medicine for Pompe disease in Europe in over 15 years

- PMLiVE

EU governments pressure manufacturers to renegotiate contracts for COVID-19 vaccines

EU officials have warned that millions of vaccine doses could be wasted due to over-supply

- PMLiVE

EC approves Roche’s Tecentriq for early-stage lung cancer

Tecentriq has now become the first cancer immunotherapy approved in Europe for the treatment of certain types of early-stage NSCLC

- PMLiVE

Roche’s Polivy receives EC approval for lymphoma therapy

The combination therapy is for patients with previously untreated diffuse large B-cell lymphoma

- PMLiVE

EC approves Novartis’ Kymriah for advanced blood cancer

Kymriah is the first CAR-T cell therapy of its kind approved in the EU for follicular lymphoma

- PMLiVE

Sanofi’s asthma treatment approved by European Commission

Dupixent is suitable for 6- to 11-year-old children who have severe asthma and type 2 inflammation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links